dr. mcdermott on the promise of pembrolizumab in non-clear cell rcc
Published 5 years ago • 89 plays • Length 1:10Download video MP4
Download video MP3
Similar videos
-
1:14
dr. jonasch on single-agent pembrolizumab in non-clear cell rcc
-
1:58
dr. mcdermott on single-agent pembrolizumab in advanced rcc
-
1:53
dr. mcdermott on long-term benefit with nivolumab in rcc
-
1:28
keynote-b61: first-line lenvatinib pembrolizumab in non-clear cell rcc
-
0:54
dr. mcdermott on immunotherapy as a standard of care in rcc
-
1:15
dr. mcdermott on single-agent versus combination immunotherapy in rcc
-
1:16
dr. mcdermott on toxicities of immunotherapy combinations in rcc
-
1:33
dr. mcdermott on single-agent nivolumab in rcc
-
15:31
northwestern drug kills glioblastoma tumor cells with priya kumthekar, md
-
8:07
tki/io comparison: lenvatinib/pembrolizumab vs cabozantinib/nivolumab vs axitinib/pembrolizumab
-
5:09
recent advances in treating advanced kidney cancer
-
1:02
dr. mcdermott on novel immunotherapy combinations in rcc
-
2:18
dr. mcdermott on immunotherapy-related aes in rcc
-
0:51
dr. mcdermott on pd-l1 expression in non-clear cell renal cell cancer
-
1:42
dr. mcdermott on immotion150 trial in rcc
-
1:22
dr. mcdermott on major findings of efficacy and safety of nivolumab in rcc
-
1:24
dr. mcdermott on nivolumab plus ipilimumab in rcc
-
1:24
dr. mcdermott on the use of anti–pd-1 combinations in mrcc
-
1:09
dr. david f. mcdermott on nivolumab in rcc
-
0:59
combining lenvatinib & pembrolizumab for non-clear cell rcc: keynote-b61 study rationale
-
1:03
dr. rini on managing the toxicity of pembrolizumab plus axitinib in mrcc
-
0:43
dr. rini on adjuvant immunotherapy in renal cell carcinoma